Gennecs, a leading company in the manufacture and development of innovative medicines and medical devices, said it has signed a number of exclusive contracts with two of the top-notch manufacturers of vaccines, serums, and biotech medicines in the world.

Additionally, the company announced their regional agency agreement for the Middle East, which shoulders the responsibility of launching the new Swiss-made swabs that are made to make Coronavirus much easier, timelier and cost effective.

Currently, this swab is utilised in most of the major European countries. Thus, introducing this swab to the Middle East markets, comes in light of supporting the medical sector in the Middle East region, as well as meeting the challenges of the second wave of the emerging Coronavirus pandemic, the company said.

To further explicate, this new swab test is deemed to be a breakthrough, and it is believed to be one of the most important and latest methods that science has reached in Europe. This European swab is manufactured in Switzerland and has obtained the approval of registration and marketing authorisation in Switzerland, France, Russia, Germany, Poland, and most of the EU countries with full world class accreditation. It is also one of fastest methods to diagnose Coronavirus with an accuracy of up to 99 per cent without laboratory intervention, Gennecs said.

Dr Nibal Dahaba, the Founding Partner and General Manager of the emerging markets region at Gennecs, commented: “Our goal at Gennecs is ensuring access to diagnosis, vaccination and treatment to each and every single patient, also one of our ongoing goals is basically attracting investments to our region with focus on biotech manufacturing in order to align with all global strategies ensuring no shortage when it comes to biotech products.”

Dahaba also added: “Gennecs is a multi-disciplinary holding company with an integrated experience in the cycle of pharmaceutical products whether innovative ones or underlicenced ones in addition to medical devices, vaccines and serums from its manufacture and development right up to the marketing stage.

Christian Frealdsson, from the Swiss company, expressed his enthusiasm about the cooperation with Gennecs by stating: “This partnership comes within the framework of our belief that the Egyptian, Arab, and African markets are some of the most promising markets at which we are seeking to place our products in the coming period. We are confident that our partnership with Gennecs will be fruitful due to the company's leadership in the field of pharmaceuticals globally and regionally.”

Gennecs Holding, it may be mentioned is the medical arm of Dabatco, one of the companies of the Eldaba Holding Group, which has its regional headquarters in Dubai together with a foot print in Canada, USA, Egypt, Russia, India and Europe.